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CDK4/6 inhibitors in breast cancer – from in vitro models to clinical trials 
Abstract  
Background: Breast cancer (BC) is one of the leading causes of cancer-related deaths 
worldwide. Standard therapies aim to disrupt pathways that regulate the growth and 
survival of BC cells. Therapeutic agents such as endocrine therapy target hormone 
dependent cancer cells and have shown to be suitable approaches in BC treatment. 
However,   in the case of metastatic BC, curative options are limited, thus strategies have been 
explored to improve survival and clinical benefit. In this review we provide an up to date 
overview of the development of anti-cancer agents, particularly the newly developed CDK4/6 
inhibitors.  
Material and methods: A search of PubMed was conducted to identify preclinical data 
surrounding the development of endocrine therapy and CDK4/6 inhibitors in early and 
metastatic BC. Clinical data were also sought using PubMed and clinicaltrials.gov.  
Results: Agents targeting estrogen and its receptor have demonstrated positive outcomes 
in clinical trial with improvements in objective responses and overall survival. However, 
patients do exhibit adverse effects and some will eventually fail to respond to endocrine 
therapy. Subsequently, the development and success of 3rd generation CDK4/6 inhibitors 
in preclinical studies have allowed for their use in clinical studies. In patients with ER+ 
BC, CDK4/6 have demonstrated dramatic improvements in progression free survival 
when in combination with endocrine therapies. Similar findings were also observed in 
metastatic disease. Adverse effects were minimal in CDK4/6 treated patients 
demonstrating their safety.   
Conclusion: CDK4/6 inhibitors are highly specific making them a safe and viable therapeutic 
for BC. Although a number of trials have demonstrated this, as a lone therapy or in 
combination, optimisation of treatment scheduling are still required in further clinical 
investigations.  
Keywords: CDK4/6; pre-clinical; breast cancer; metastasis 
 
Introduction  
As the most common malignancy diagnosed in women, Breast Cancer (BC) is the 
second leading cause of cancer-related deaths worldwide [1].  BC is diagnosed in one in 
eight women with a 3.4% risk of mortality. It also accounts for 29% of new cancer cases 
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in the USA with 5-10% presenting with metastatic disease [2]. The 5 year overall 
survival rates are relatively high (90%) in early stage disease. However in metastasis, the 
5 year overall survival is dramatically decreased to 25%. In the metastatic setting, 
therapies for patients are mainly palliative and often accompanied with adverse effects. 
Depending on the subtype of BC, patients have a broad spectrum of therapies in an 
attempt to provide better outcomes. For example, endocrine receptor positive BCs are 
heavily dependent on the expression of the estrogen (ER) and/or progesterone (PR) 
receptors. Upon activation, these receptors initiate signalling pathways that regulate 
cellular processes such as proliferation, apoptosis and angiogenesis that contribute to 
cancer progression [3] (figure 1). This dependence on ER/PR signalling has resulted in 
the development of endocrine therapies that target these receptors and their downstream 
pathways, including ER/PR blockers, aromatase inhibitors and ER own-regulators.    
As little as 5% of patients are diagnosed with stage IV BC at initial diagnosis, most cases arise 
after endocrine therapy or chemotherapy [4]. Although endocrine therapies are associated with 
high rates of clinical benefit, disease progression is often observed after one year of first line 
treatment [5]. ER/PR positive disease cease to respond to endocrine treatment due to acq ired
resistance caused by either the loss of endocrine receptors and/or activation of ER/PR-
independent signalling pathways [6,7].  This resistance may in part result from the tumour 
losing the dependency on hormone-ER signalling and instead utilising alternative survival 
pathways that act through the cyclin-dependent kinase (CDK)-cyclin and retinoblastoma (Rb) 
interaction [3]. The CDKs are a family of serine/threonine kinases that are key rgulators of 
the cell cycle. Subgroups of CDKs, such as CDK4/6, are shown to have a critical role in BC 
pathogenesis and tumourigenesis, leading to the development of CDK targeting agents. 
Known as CDK inhibitors (CDKi), these drugs have been shown to improve clinical outcome 
and delay the onset of breast tumour progression, particularly when used in combination with 
endocrine therapy [8,9].               
 
Mechanisms underlying BC- the role of cyclins 
 
Cyclin-CDK pathways regulate the cell cycle 
The cell cycle is split into four phases, growth phase (G1), DNA synthesis (S), a second 
growth phase (G2) and mitosis (M) (figure 2). Passage from one phase to the other is tightly 
regulated by molecular checkpoints, e sential for the detection of DNA damage as well as 
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providing the opportunity to repair defects prior to mitosis [10]. The checkpoints are regulated 
by a number of cyclins, regulatory subunits of the CDK-cyclin holoenzyme, and their 
respective CDKs. In particular, the irreversible transition from G1-S phase is heavily 
dependent on the cyclin D-CDK4/6-Rb pathway [11]. The cyclin family is divided into A-, B-, 
D- and E- types, of which, cyclin D and cyclin D1 are the best characterised of the cyclin 
subtypes [12]. During cell division, cyclin D1 is found to have strong interactions with CDKs, 
specifically CDK4 and CDK6. Another major checkpoint regulator is the retinoblastoma 
protein (Rb), which has a role in inhibiting the cell from entering the cell cycle by repressing 
the E2F family of transcriptional factors. When initiating the cell cycle process, the cell 
produces cyclin D1 that goes on to form an activating complex with CDK4/6. The cyclin D1-
CDK4/6 complex then promotes the phosphorylation of Rb, which, in its phosphorylated state 
lifts its transcriptional repression of E2F. E2F then proceeds with the transcription of S-phase 
genes, such as cyclin E, which forms a complex with CDK2. The cyclin E-CDK2 complex 
further phosphorylates Rb and other regulators of the G1/S phase checkpoint, establishing a 
positive feedback loop resulting in the irreversible transition and progression through the cell 
cycle [13].  
 
Cyclin-CDK pathways in BC pathogenesis  
Uncontrolled cell division is a defining characteristic, and a hallmark of cancer [14]. 
Mutations in cell cycle regulators, particularly within the cyclin-CDK-Rb pathway, have been 
found to be an underlying cause in the disruption of controlled proliferation. In fact, the 
overexpression of cyclin D1 is evident in 50% of all BC cases, resulting in aberrant 
phosphorylation of Rb, demonstrating its crucial role in the development of disease [15-17]. 
Analysis of BC subtypes by the Cancer Genome Atlas has shown that cell cycle genes vary in 
different subtypes [18]. For example, cyclin D1 amplification is most frequently found in 
LBC-A (29%), -B (58%) and HER2 positive (38%) subtypes. Moreover, both cyclin D1 and 
CDK4 were observed to be highly amplified in LBC-B and HER2 cancers (58% and 25%, 
respectively). It is also known that the loss of heterozygosity of the Rb gene locus occurs in 
20-30% of BC [19]. In the case of ER positive BCs, estrogen signalling is essential for he 
growth, proliferation and survival of the tumour. Estrogen signalling also leads to the 
upregulation of cyclin D1, which in turn activates CDK4/6 and downstream signalling 
molecules [20]. As mentioned previously, endocrine therapy is the first-line approach in the 
treatment of metastatic ER positive BC, however not all ER positive cancers respond and 
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resistance is common. Thus, it has been proposed that inhibition of cell cycle regulators may 
be an effective method of targeting ER positive BC.        
 
Therapeutic targeting of BC 
 
Endocrine therapy  
The foundations of endocrine-directed cancer therapy were first established in the late 1800’s 
by George Thomas Beatson. He showed that oophorectomy (removal of the ovaries) 
conducted on BC patients resulted in improved outcomes hypothesising that ovaries 
maintained the existence of the cancer within the breast [21]. In fact, he was explaining the 
stimulatory effect of the female ovarian hormone, estrogen, before its discovery. Thus, 
endocrine therapies commonly used in ER positive BCs target ERs by either blocking them 
(selective estrogen-receptor modulators (SERMs)), inhibiting estrogen production (aromatase 
inhibitors AIs), or actively downregulating them (selective estrogen-receptor degraders 
(SERDs)).  
 
SERMS are a group of ER antagonists that block the receptor, thereby preventing downstream 
signalling pathways in the presence of estrogen (figure 1). Tamoxifen was identified in the 
1970s as a potential anti-ER in induced mammary carcinogenesis [22]. Due to the success and 
safety of tamoxifen in preclinical studies [23], a large scale clinical trials in early BC in the 
late 1990’s was initiated.  The EBCTCG studied tamoxifen as an adjuvant therapy in around 
30,000 women and found dramatic falls in recurrence rates after a 10 year follow-up, 
proportional to the duration of treatment (fall in recurrence at 1 year 21%, 2 years 29% and 5 
years 47%). In addition, mortality rates also dropped in proportion to treatment duration, 
suggesting that prolonged exposure is more effective in targeting BC with tamoxifen [24]. Of 
the 30,000 women enrolled in the trials, 8,000 exhibited ER low/negative tumours. In these 
cases, it was found that tamoxifen had little effect, instead showing benefits for ER positive 
pre- and postmenopausal women [24]. Parallel investigations were undertaken to determine 
the safety and treatment scheduling [25-27]. Postmenopausal symptoms were the most 
commonly observed side effects, including hot flushes, night sweats, irregular menses and 
vaginal dryness, discharge or irritation [27]. Life-threatening side effects were minimal, 
however an increase in the risk of a thromboembolic event occurring was greater in tamoxifen 
treated patients as described in the P1 study by The National Surgical Adjuvant Breast and 
Bowel Project (NSABP) [28,29]. From these studies, it was concluded that the benefits of 
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tamoxifen treatment outweighed the adverse effects. Furthermore, adjuvant tamoxifen therapy 
was determined to be administered for a duration between 2 and 5 years providing a 
significant survival advantage [30]. More recently however, the ATLAS study showed 
continued tamoxifen treatment for 10 years resulted in a reduction in the risk of BC recurrence 
and significant reductions in BC mortality [31]. These findings were conformed by the 
aTTOm trial conducted between 1991-2005 [32]. Since these studies show benefit with 
continued 10-year treatment with tamoxifen compared to 5 years, most oncologists now 
recommend 10 years as a standard of care. 
       
Aromatase inhibitors (AIs) inhibit the production of estrogen by targeting and suppressing the 
aromatase enzyme (figure 1). Prior to the menopause, ovarian-derived aromatase is 
responsible for the production of circulating estrogen. Post menopause, circulating estrogen 
production predominantly occurs in fat and muscle as well as other estrogen-sensitive organs 
such as breast, uterus and vagina. Thus, AI therapy is commonly used in postmenopausal 
women since the inhibition of ovarian-aromatase decreases ovary-derived estrogen setting up 
a negative feedback loop to the pituitary gland, eliciting further production of LH and 
subsequently ovarian estrogen in the pre-menopause setting, rendering the AI ineffective.  
 
Studies using AIs have been reviewed extensively in the early BC setting [33,34]. When 
compared to tamoxifen, 10 year mortality rates are reduced by 15% in AI treated patients over 
5 years of treatment [35]. Further studies such as the Breast International Group (BIG) 1-98 
and Arimidex Tamoxifen Alone or in Combination (ATAC) trials demonstrated the advantage 
of adjuvant AI (letrozole and anastrozole respectively) therapy compared to tamoxifen 
[36,37]. The Intergroup Exemestane Study (IES) trial introduced exemestane (an AI) therapy 
following 2-3 years of tamoxifen treatment for the remainder of the 5 year regimen [38]. The 
overall survival rate was improved on AI treatment compared to continued tamoxifen 
treatment [39]. A phase3 randomised double-blinded study, MA. 17, was conducted to 
investigate whether treatment with the AI letrozole after 5 years on tamoxifen reduces the risk 
of late recurrences [40]. Improved disease free survival and improved overall survival in node-
positive patients with extended letrozole treatment was observed in comparison to placebo 
[41]. Importantly, the above studies illustrate the safety of AI therapy as the lack of 
documented adverse events such as cardiac-related complications and endometrial cancers, 
otherwise observed in tamoxifen treated patients [42] 
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AIs have also been extensively used as a therapeutic strategy in targeting metastatic BC in 
postmenopausal women. Around 35 trials have investigated the use of AIs as first- and second 
line treatments [43]. Anastrozole and letrozole have shown to have good efficacy and 
tolerability in phase 2 and phase 3 trials. When compared to tamoxifen, anastrozole 
demonstrated improved clinical benefit (defined as complete or partial response ≥ 24 weeks) 
in 59% of postmenopausal women with advanced BC, compared to 46% of the tamoxifen 
treated patients, as a first-line therapy [44]. Similar results were observed in a randomised 
phase 3 trial in ER positive advanced BC patients, reporting that median time to disease 
progression was significantly higher in anastrozole treated patients compared to tamoxifen 
treated patients [45]. It was also demonstrated that letrozole significantly improved median 
time to progression, objective response and overall survival in a number of phase 3 studies 
when compared to tamoxifen in advanced BC patients [46-48].  
 
The SERD, fulvestrant, was first compared to anastrozole as an adjuvant therapy in a phase 3 
trial [49,50]. No significant differences were observed in clinical outcomes such as median 
time to progression and objective response rate and this is not routinely used in this setting. In 
the metastatic setting, when compared to tamoxifen as first line treatment, little difference was 
observed in the median time to progression between treatment groups [51]. The combination 
of anastrazole and fulvestrant was also investigated in two trials [52,53]. In these studies, a 
large proportion of the patients had received prior tamoxifen treatment and both showed that 
combination therapy did not result in improved overall survival compared to anastrazole 
alone. The results observed in these earlier trials were limited by the low dose of fulvestrant 
administered. Due to its poor solubility properties, fulvestrant is administered by 
intramuscular injection at 250mg every 28 days. To identify more effective approaches, the 
dose effect of fulvestrant on a range of biomarkers was explored. ER positive BC patients 
were given 500mg every 28 days and an additional 500mg on day 14 of the first week as 
compared to 250mg every 28 days. On day 28, a significant increase in down-regulation of Ki-
67 was observed in patients receiving the higher dose compared to the initial treatment plan 
(78.4% vs 47.4%) [54]. It was also discovered that a 25% reduction in ER expression wa 
associated with the 500mg dose compared to 13.5% in the 250mg dose. A comparison 
between the two doses was undertaken by the CONFIRM phase III trial, showing that 
although ORR were similar between patients receiving 500mg and 250mg and both doses 
were well tolerated, progression free survival and overall survival were significantly improved 
in the 500mg arm [55]. With this, a phase II study consisting of 205 patients compared 500mg 
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fulvestrant to 1mg anastrozole as first line treatment [56]. The median time to progression in 
fulvestrant patients was significantly higher (23.4 months) compared to anastrozole (13.1 
months). Overall survival was also higher in the fulvestrant group (54.1 months) compared to 
anastrozole treated patients (48.4 months). These findings led to the development of a 462 
patient double-blind phase 3 trial, the FALCON study. Here, to confirm the efficacy of 
fulvestrant (500mg), it was compared with anastrazole in endocrine therapy-naïve women 
[57]. Patients receiving fulvestrant showed significantly longer disease free progressi n 
(median 16.6 months) compared to the anastrazole group (median 13.8 months) with similar 
adverse event rates. This study demonstrates the superior efficiency of fulvestrant in patients,
predominantly with metastatic BC to the bone, that have not previously undergone hormone 
therapy.   
From the trials described above, it is clear that endocrine therapy is an effective approach in 
ER positive BC. However, response to endocrine therapy heavily relies on ER expression, thus 
the loss of ERs results in  de novo resistance which is not uncommon (15-20%) [3]. However, 
a high proportion of ER positive BC patients (30-50%) will relapse following endocrine 
therapy [58]. One of the underlying causes of resistance-mediated relapse are mutations of the 
ER gene, ESR1. Gain of function ESR1 mutations are found in 20% of patients treated with 
endocrine therapies. Moreover, mutations in the ligand-binding domain result in ER-
independent tumour growth and partial resistance to endocrine therapy [59]. Point missense 
mutations in the ESR1 gene are also associated with constitutively active ER activity, however 
these are rarely found in the primary tumour. Instead their frequency is 30-times higher in 
metastatic lesions [60]. Meta-analysis conducted by Zhang et al confirmed that patients with 
plasma ESR1 mutations exhibited worse progression free survival and overall survival 
compared to wild-type ESR1. In addition, they showed that ESR1 mutations were associated 
with shortened progression free survival after AI therapy, though this correlation was not 
observed in fulvestrant-treated patients [61]. Since endocrine signalling dependence is 
abolished in these cases, agents that target alternative pathways, such as the cell cycle process 
and its downstream pathways, have been sought.  
 
CDK inhibitors   
Preclinical studies of CDK inhibitors 
The success of CDK inhibitors is a result of decades of research aiming to identify the most 
effective and safest molecule that could be used to target CDKs and inhibit their actions. CDK 
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inhibitors are separated into 3 categories, first-, second- and third generation, def ned by their 
discovery and targets (Table 1).  
 
First generation inhibitors exert their effects through non-specific targeting of CDKs, they are 
therefore termed ‘pan-CDK’ inhibitors. Flavopiridol (alvociclib), one of the most studied 
compounds of this class, has been shown to target CDK1, CDK2, CDK4, CDK6, CDK7 and 
CDK9, demonstrating its pan-CDK inhibitory potential [62,63]. Initially discovered to inhibit  
proliferation in haematological cancer cell lines in vitro [64], subsequent studies demonstrated 
that flavopiridol inhibited cell cycle progression in G1 or G2 phase of the human breast 
carcinoma MCF-7 cell line in a CDK1-dependent manner [65]. A later study showed that in 
addition to its anti-proliferative effects, flavopiridol also exhibited pro-apoptotic potential in 
vitro and in vivo [66]. Disappointingly, flavopiridol did not prove to be as successful as 
expected in solid tumours due to toxicity issues and lack of efficacy [67], although some 
benefits were observed in haematological malignancies, including improved response rates 
and progression free survival [68]. As a result, no phase 3 studies have been undertake  and 
the development of flavopiridol has been discontinued.  
 
Second generation CDK inhibitors were developed in an attempt to target specific CDKs, 
aiming to improve efficacy and clinical outcomes. One example is dinaciclib, identified as a 
potent inhibitor of CDK1 and CDK2 and demonstrating superior potential in supressing Rb 
phosphorylation when compared to flavopiridol [69]. Dinaciclib showed increased pro-
apoptotic activity as well as inhibition of bromodeoxyuridine incorporation in over 100 
tumour cell lines. In the same study, xenograft models of solid tumours demonstrated 
significant tumour regression following treatment with dinaciclib [69]. These promising 
results prompted its introduction into a phase 1 study in which dinaciclib was determined to be 
safe and tolerated in a range of solid tumours, including colorectal, ovarian and brest [70]. 
However, a subsequent phase 2 trial demonstrated that dinaciclib showed poor efficacy 
compared to the chemotherapeutic agent capecitabine [71]. The trial was ceased after an 
interim analysis revealed that the time to disease progression in dinaciclib treated patients was 
inferior to that of patients receiving capecitabine [71]. The lack of success of these inhibitors 
may be attributed to the limited understanding we have of their precise mechanism of action. 
Due to the low specificity of the agents, it is difficult to identify which CDKs are inhibited and 
thus its underlying anti-tumour mechanism. It was therefore imperative to identify molecules 
that were highly specific in targeting certain CDKs involved in particular pathways. For 
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example, purely targeting CDK4 and CDK6 would theoretically result in cytostatic G0/G1 
arrest by inhibiting Rb phosphorylation. Subsequently, chemical screening and optimization 
discovered potent CDK4/6 inhibitors composed of pyrido-[2,3-d]pyrimidin-7-one with a 2-
amino pyridine side chain at the C2 position [72]. These compounds are known as third 
generation CDK inhibitors (figure 2). 
 
Preclinical studies of third generation CDK4/6 inhibitors  
Upon further development and optimization of third generation inhibitors, palbociclib (PD-
0332991, Pfizer), ribociclib (LEE011, Novartis) and abemaciclib (LY-2835219, Eli Lilly) 
were identified as selective CDK4/6 inhibitors [73,74]. These compounds act by targeting the 
ATP-binding pocket of CDK4 and CDK6, thereby inhibiting their ability to phosphorylate Rb, 
resulting in cell cycle arrest at the G1-S checkpoint [75].  
 
Palbociclib is a highly specific inhibitor of CDK4 with an IC50 value of 0.011 たmol/L (to 
CDK4/cyclin D1 and D3), without activity against other CDKs or to 32 other protein kinases 
tested [73]. Moreover, palbociclib inhibited CDK6 with the same affinity as CDK4 (0.015 
たmol/L), demonstrating its specificity for CDK4/6.  Rb phosphorylation was found to decrease 
in response to palbociclib treatment in MDA-MB-435 breast carcinoma cells. In addition, 
palbociclib inhibited proliferation of breast, colon and lung carcinoma cells, with 95% of the
cells arrested in the G1 phase [73]. Further analysis conducted on several BC cel lines showed 
that palbociclib inhibited growth in a cytostatic manner, with luminal ER positive and HER2 
positive cancer cell lines showing the highest sensitivity [76]. It was also demonstrated that 
following 48 hours of incubation with palbociclib, Ki67 staining is suppressed in ex vivo 
human BC samples [77]. These results were reproduced in human xenograft mouse models 
[73]. Mice were transplanted subcutaneously with a range of cancer cells (including breast, 
lung and colon) and once the tumours were palpable, palbociclib treatment commenced using 
a dose of 150mg/kg daily for 14 to 28 days. Analysis of tumours after treatment showed 
evidence of inhibition of Rb phosphorylation and reduced Ki67 staining. Furthermore, tumour 
regression and a delay in tumour growth was also observed in response to palbociclib. An 
interesting finding was described when palbociclib was studied in combination with tamoxifen 
in resistant cells. Tamoxifen-resistant MCF-7 breast adenocarcinoma cells showed sensitivity 
to palbociclib alone and increased sensitivity to tamoxifen when treated in combination [76]. 
These results provide foundational evidence for the development of palbociclib as a BC 
therapeutic.  
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Ribociclib has also shown to exhibit antitumour effects , when screened against 50 BC cell 
lines, ribociclib demonstrated inhibitory activity, mostly against ER positive cell lines [78]. 
Inhibition of tumour growth was also observed in response to ribociclib treatment  in in vivo
xenograft models of ER positive BC [78]. Interestingly, using patient derived xenograft (PDX) 
models, ribociclib has shown to be a potent antitumour agent when combined with alpelisib (a 
PI3K inhibitor) as well as letrozole and fulvestrant, significantly improving response rates and 
progression free survival [79]. 
 
Abemaciclib was identified by researchers at Eli Lilly and Company Research Laboratories 
[74]. Like palbociclib, abemaciclib showed high specificity for CDK4 and CDK6 with low 
affinity for CDK9. An initial study investigated the anti-proliferative effects of abemaciclib in 
BC cells. As expected, inhibition of Rb phosphorylation was observed and in turn decreased 
proliferation of cells that were arrested in G1 [74,80]. In a panel of 44 BC cell lines, ER 
positive/HER2 negative and Her2-amplified cancer cell lines demonstrated highest sensitivity 
to abemaciclib [80]. When investigated in vivo, daily abemaciclib treatment at a dose of 
75mg/kg resulted in regression of BC xenografts [80]. However, within the first week of 
withdrawal of abemaciclib, tumour growth resumed. BC xenograft tumours from animals 
treated with abemaciclib showed evidence of inhibited Rb phosphorylation [74]. It has also 
been demonstrated that abemaciclib treatment increases its effects on tumour regression 
(breast and colon tumours) when used in combination with cytotoxic agents [74,80]. These 
data support the development of abemaciclib in clinical trials, either alone or in combination 
in ER positive BC, as discussed below. 
 
Clinical trials of CDK4/6 inhibitors in metastatic BC as monotherapy or in combination 
with endocrine therapy 
 
Palbociclib 
As combination therapy with endocrine treatment was supported by positive findings in 
preclinical studies, 12 menopausal women with ER positive metastatic BC were enrolled in a 
phase 1 study investigating the effects of palbociclib combined with the AI inhibitor letrozole. 
Nine patients demonstrated tumour stabilisation and 3 patients exhibited partial response, with 
few dose-limiting toxicities and no drug-drug interactions [81]. 
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The success of the activity and safety of palbociclib phase 1 trials allowed the initiation of 
phase 2 trials. A non-randomised, single-arm phase 2 trial using palbociclib as a monotherapy 
was conducted in 37 patients with Rb positive, pre-treated, advanced BC (33 with ER positive 
disease) [82].  Patients with ER positive tumours showed a median progression-free survival 
of 4.5 months compared to 1.5 months in patients with ER negative tumours. In addition to 
this, seven patients, all within the ER positive group, showed clinical benefit in response to 
palbociclib. Interestingly, patients that had undergone fewer previous treatment lines showed 
better clinical benefit rates compared to those who were heavily pre-treated. Following the 
phase 1 trial by Slamon et al, a larger, open-label randomized phase 2 study was undertaken 
further assessing the safety and efficacy of palbociclib plus letrozole compared to letrozole 
alone [83]. The PALOMA-1 study (palbociclib: on going trials in the management of breast 
cancer-1) enrolled 165 ER positive metastatic BC patients with no prior systemic treatment 
and evidence of local recurrent disease not amenable to surgery. Patients were divided into 
two cohorts; patients in cohort 1 were assigned based on their ER positive, HER2 negative 
status whereas cohort 2 included patients that exhibited cyclin D1 amplification and/or loss of 
p16. Having two cohorts would allow for the assessment of both the efficacy of palbociclib in 
combination with letrozole, and whether additional biomarkers were required for patient 
selection. Within each cohort, patients were assigned two stratification factors, disease site 
(bone only, visceral and non-visceral) and disease-free interval (> 12 months frm the end of 
adjuvant treatment to recurrence vs < 12 months or less from the end of adjuvant treatment to 
recurrence or de novo metastatic disease). Initial exploratory analysis was intended for cohort 
1 and primary endpoint analysis for cohort 2. However, results from an interim analysis 
resulted in primary endpoint analysis being conducted in the combined populations of cohort 1 
and 2. This was due to the suspension of enrolment into cohort 2 because of ‘clinical 
meaningful activity’ demonstrated by patients in cohort 1. The interim analysis also 
demonstrated that patient selection  would not be improved based on cyclin D1 amplification 
and/or loss of p16. When analysed separately at the cut-off date, it was shown that patients
receiving letrozole alone had a median progression-free survival of 10.2 months, this was 
significantly higher (20.2 months) in the cohort receiving combination therapy [83]. Within 
cohort 1, the median progression-free survival was 5.7 months in the letrozole group and 26.1 
months in the palbociclib plus letrozole group. In cohort 2, the median progression-free 
survival for letrozole and combined therapy was 11.1 and 18.1 months, respectively. The data 
show that patients with ER positive advanced BC had improved clinical outcome in response 
to palbociclib treatment combined with letrozole. Again, as observed in previous clinical 
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trials, neutropenias and other adverse events such as leukopenia, fatigue and diarrhoea were 
common, more so in the combined therapy group, suggesting that palbociclib exerts CDK 
inhibitory effects on haematological progenitor cells.  
 
Further analysis on safety and quality of life was undertaken in the phase 3, PALOMA-2, trial. 
This double-blind study enrolled post-menopausal women with ER positive, HER2 negative, 
advanced BC (n=666) who had received no previous systemic endocrine therapy [84]. Patients 
were treated with palbociclib plus letrozole, or letrozole plus placebo. In the palbociclib plus 
letrozole group, median progression-free survival was 24.8 months, considerably higher than 
the 14.5 months in the letrozole alone group. Neutropenia was the most common adverse 
effect, reported in 66.4% of palbociclib plus letrozole patients, compared to 1.4% of the 
placebo-letrozole group. However, less than 2% of palbociclib-letrozole patients suffered from 
febrile neutropenia, confirming the safety of the combination as a first line therapy. In a 
proceeding phase 3 study, the PALOMA-3 trial, palbociclib was investigated in combination 
with fulvestrant as second line therapy in patients with metastatic BC [85]. Unlike the 
PALOMA-2 trial, patients aged 18 years or older with previous endocrine therapy and disease 
relapse or progression were eligible to take part. Patients were treated with palbociclib and 
fulvestrant (n=347) or with fulvestrant and placebo (n=174). Palbociclib plus fulvestrant 
treated patients had a median progression free survival of 9.5 months, significantly higher than 
the fulvestrant and placebo group (4.6 months). Moreover, grade 3 or 4 adverse effects were 
observed in 73% of the palbociclib and fulvestrant patients compared to the 22% in the 
fulvestrant and placebo group, however severe adverse effects were 13% and 17% 
respectively [85]. In a more recent follow up of the PALOMA-3 study, it was shown that the 
median overall survival was 34.9 months in the palbociclib plus fulvestrant group compared to 
28 months in the placebo group [86]. In addition to this, subgroup analyses showed that 
patients that were sensitive to the previous line of therapy exhibited a higher degree of benefit 
of palbociclib treatment. Contrarily, patients that demonstrated endocrine resistance did not 
obtain such benefit. It was also found that the median overall survival of patients with visceral 
metastatic disease was 27.6 months in palbociclib plus fulvestrant group, 2.9 months higher 
than for patients receiving placebo plus fulvestrant. In the parallel ‘no visceral metastatic 
disease’ group, palbociclib plus fulvestrant group demonstrated a median overall survival of 
46.9 months, significantly higher that the placebo plus fulvestrant group (35.4 months).  These 
results demonstrate the improved progression free survival in response to palbociclib 
treatment, regardless of previous endocrine therapy, menopausal or metastatic status.   
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Abemaciclib  
Similar observations to those obtained with palbociclib were documented in phase 1 trials with 
abemaciclib, showing delayed disease progression and stabilised disease in the BC setting 
[87,88]. Patnaik et al sought to determine dose-limiting toxicity and safety of abemaciclib 
applying two dosing strategies, a once-daily dose of 225 mg or a 12-hourly dose of 200 mg. 
Patients receiving 225 mg/daily did not reach the maximum tolerated dose, however one out 
of 7 patients treated 12-hourly experienced grade 3 fatigue [88]. This established the 12-hourly 
dosing regimen for the first phase 2, MONARCH-1, trial with abemaciclib monotherapy in 
patients who had progressed on or after prior endocrine therapy and had 1 or 2 chemotherapy 
regimens in the metastatic setting [89]. Median progression-free survival of treated patients 
was 6 months and clinical benefit rate was 42.4%. Diarrhoea, fatigue and nausea were 
described as the most common adverse effect, but abemaciclib was found overall to be safe 
and effective. Consequently, a randomised phase 3 trial, MONARCH-2, was carried out to 
investigate the safety of abemaciclib plus the selective ER degrader (SERD) fulvestrant [90] in 
patients who had progressed while receiving neoadjuvant or adjuvant endocrine therapy (ET), 
≤ 12 months from the end of adjuvant ET, or while receiving first-line ET for metastatic 
disease. Of the 669 patients enrolled, 446 were assigned to abemaciclib and fulvestrant 
treatment, whereas the remaining 223 were treated with placebo plus fulvestrant. Progression-
free survival was significantly increased in the former group (16.4 versus 9.3 months, 
respectively). Objective response rate (ORR) was also observed to be considerably higher in 
patients treated with abemaciclib plus fulvestrant, 48.1%, compared to the control group, 
21.3% [90]. A subsequent phase 3 trial of abemaciclib, MONARCH-3, was conducted in 
2017. Unlike in MONARCH-2, postmenopausal women were enrolled without having 
received previous systemic treatment for their metastatic disease and were treated with 
abemaciclib or placebo in combination with a non-steroidal AI (letrozole or anastrazole) [91]). 
Again, progression-free survival was reported to be significantly longer in the abemaciclib 
than the placebo cohort, this was also the case for the ORR (59% versus 44% respectively). 
Adverse events included neutropenia (21.1% versus 1.2%), diarrhoea (9.5% versus 1.2%) and 
leukopenia (7.6% versus 0.6%) [91]. Abemaciclib (plus fulvestrant or AI) treatment resulted 
in a lower proportion of patients suffering with neutropenia compared to those reported in the 
PALOMA trials of palbociclib, but a higher incidence of diarrhoea, reflecting the high 
specificity of abemaciclib.   
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Ribociclib  
The first in-human phase I clinical trial of ribociclib was conducted in 2014,   investigating its 
safety and tolerability as a lone treatment [92]. 132 patients were enrolled to d termine the 
maximum tolerated dose (MTD), the recommended dose for expansion (RDE) and safety of 
ribociclib in advanced Rb positive solid tumours (including ER positive BC). It was 
established that the MTD and RDE were 900 mg/day and 600 mg/day respectively. Although 
treatment-related adverse events were observed, such as neutropenia, leukopenia, fatigue and 
nausea, these were more frequently observed at the MTD compared to the RDE (neutropenia 
(46%; 27%), leukopenia (43%; 17%), fatigue (45%; 2%), and nausea (42%; 2%) respectiv ly). 
The anti-proliferative effects of ribociclib were confirmed by the reduced Ki67 levels in 
biopsies, demonstrating its acceptable safety profile and clinical activity. An early phase 1b 
trial conducted in 2016 showed similar safety and tolerability results in postmenopausal 
patients with advanced ER positive BC treated with ribociclib in combination with letrozole 
[93]. Although the same adverse events were observed, the most interesting finding was that 
the ORR and clinical benefit rates were considerably higher in patients that had no previous 
treatment (39% and 73%, respectively) compared to treated patients (5% and 32%, 
respectively). In light of these results, a larger phase 3 trial was conducted, named
MONALEESA-2, consisting of 668 postmenopausal women with ER positive metastatic BC 
[94]. The aim of the MONALEESA-2 trial was to determine the safety of ribociclib in 
combination with letrozole as first-line therapy. Patients treated with ribociclib and letrozole 
demonstrated a progression free survival rate of 63%, significantly higher than that observed 
in the placebo plus letrozole treated group (42%). Overall response rates were also improved 
in the ribociclib and letrozole group compared to the placebo group (52.7% and 37.1% 
respectively). Adverse events were observed at higher rates in the ribociclib group compared 
to the placebo group (neutropenia (59.3% vs 0.9%) and leukopenia (21.0% vs. 0.6%)). Follow 
up results were published at a later interim and it was shown that patients treated with 
ribociclib and letrozole exhibited a median progression free survival of 25.3 months, whereas 
the placebo group showed a median of 16 months [95]. Similar results were also observed in 
premenopausal women treated with ribociclib and tamoxifen (and other combinations of 
aromatase inhibitors) in the MONALEESA-7 trial [96]. More recent analysis of the 
MONALEESA-7 trial was able to assess the overall survival in ribociclib (in combination 
with endocrine therapy) treated patients [97]. Here, it was sown that patients treated with 
ribociclib exhibited longer overall survival at 42 months (70.2%) compared to that of the 
placebo group (46.0%). This was also reflected by the lower number of deaths in the ribociclib 
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group (83/335 (24.8%) compared to 109/337 (32%) in the placebo group). Results from this 
analysis is the first of the CDK 4/6 clinical trials to report an overall survival benefit. 
Overall survival outcomes from other studies are awaited. However, considering the 
progression free survival benefit is very similar between all agents it is anticipated that 
OS benefit may also be similar.   
Fulvestrant was also investigated in combination with ribociclib as second line treatment in 
484 postmenopausal women [98]. This trial, MONALEESA-3, saw patients’ progression free 
survival improve with ribociclib plus fulvestrant (20.5 months) as opposed to fulvestrant and 
placebo (12.8 months). Overall response rates were also higher in the ribociclib and 
fulvestrant group (40.9% vs 28.7%). Interestingly, the treatment effects of ribociclib were 
consistent in both patients that were treatment-naïve and those who had received prior therapy. 
These results demonstrate the safety of ribociclib and its promising option as first- and econd-
line therapy in advanced metastatic BC.       
 
Clinical trials of CDK4/6 inhibitors in early BC in combination with endocrine therapy 
The promising results of the CDK4/6 inhibitors in the advanced setting has forced for their 
investigation in early BC (summarised in Table 2). A large phase 3 trial currently recruiting 
approximately 5600 patients aims to study the effects of palbociclib in addition to adjuvant 
endocrine therapy in patients with stage 2 or stage 3 BC
(ClinicalTrials.gov identifier: NCT02513394 (PALLAS)). In this study, a comparison will be 
made between a 2-year palbociclib and adjuvant endocrine therapy group and an adjuvant 5- 
year endocrine therapy only group. Initially, the primary outcome measure will be invasive 
disease free survival followed by further outcomes such as the safety of 2 years palbociclib 
with endocrine therapy and distant recurrence-free survival. Ribociclib and abemaciclib are 
also under investigation in combination with endocrine therapies in stage 3 high risk BC 
(ClinicalTrials.gov identifier: NCT03078751 (EarLEE-1) and NCT03155997 (monarchE) 
respectively). The EarLEE-1 and monarchE studies, will investigate the safety and efficacy of 
ribociclib (2 years) and abemaciclib, respectively, in combination with adjuvant endocrine 
therapy compared to endocrine therapy alone. Similarly to the above study, invasive disease 
free survival will primarily be measured followed by distant recurrence free survival and 
overall survival.  
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Palbociclib will also be investigated in another phase 3 trial, recruiting patients with residual 
disease and high risk of relapse (ClinicalTrials.gov identifier: NCT01864746 (PENELOPE-
B)). In this study however, the assessment of palbociclib (standard 21 days on, 7 days off  for 
13 treatment cycles) will be conducted as a post-neoadjuvant (chemotherapy) treatment in pre- 
and postmenopausal women. Here, invasive disease free survival for palbociclib will be 
compared to a placebo after neoadjuvant chemotherapy. A single-arm trial has also been 
designed to study palbociclib as a neoadjuvant therapy in stage 2-3 ER positive BC [99]. In 
this study, 50 patients were treated with anastrazole for 4 weeks followed by the addition of 
palbociclib for four 28 day cycles. Complete cell cycle arrest (CCCA) was used as a primary 
end point. Patient biopsies showed that palbociclib treated patients had significantly higher 
CCCA rates compared to anastrazole monotherapy (87% vs 26% respectively). It was also 
noted that the anti-proliferative effects of palbociclib were quickly diminished when treatment 
was withheld prior to surgery, suggesting that the dormant effects are dependent on continuous 
treatment. The neoMONARCH phase 2 trial, abemaciclib was used in combination with 
anastrazole in 220 postmenopausal women (ClinicalTrials.gov identifier: NCT02441946). 
Similar results were observed as the previous study where cell cycle arrest was more profound 
(i.e. reduced Ki67 and higher CCCA rates) in abemaciclib alone, and in combination, 
compared to anastrazole alone. These studies demonstrate the rising interest in CDK inhibitors 
for early and advanced ER positive breast cancer. They also provide strong arguments to 
consider their use in neo- and adjuvant settings. 
 
Combining CDK4/6 inhibitors with other systemic anti-cancer treatments. 
Two interesting pathways exist that are involved in the regulation of cell survival, growth and 
proliferation. The phosphatidylinositol-3-kinase (PI3K)/Akt and the target of rapamycin 
(mTOR) signalling systems are highly interconnected and often considered as a single 
pathway. The PI3K/Akt pathway has a vital role in survival during cellular stress [100].
Similarly, the mTOR pathway is dependent on external signals, such as growth factors, 
oxygen and amino acids. It functions by translating these signals through downstream 
signalling molecules, by phosphorylating S6K1 and 4EBP, which in turn promote the 
production of proteins, lipids and nucleotides that are essential for growth, survival and 
proliferation (figure 3) [101]. It is also known that mTOR activation leads to the production of 
cyclin D1 [102]. These pathways play important roles in cellular processes and dysregulation 
or mutations can result in oncogenic outcomes. For example, the overexpression of the 
receptor tyrosine kinase, ErbB2, is found in approximately 25% of BCs. In these tumours, the 
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PI3K/Akt pathway is constitutively activated resulting in uncontrolled proliferation [103]. 
Thus, the mTOR pathway has become an interesting target for anti-cancer therapeutics, with 
the use of mTOR inhibitors previously reviewed [104]. Numerous mTOR inhibitors have been 
investigated in a range of cell lines, including BC, and have progressed into clinical trial 
[105,106].  
 
mTOR inhibitors have been recently proposed to be used in combination with CDK inhibitors. 
In 2016, an in vitro study investigated the effects of the mTOR inhibitor rapamycin combined 
with the CDK inhibitor purvalanol on androgen dependent, and independent, prostate cancer 
cells. Co-treatment with rapamycin and purvalanol resulted in apoptosis through the 
modulation of upstream targets of PI3K/Akt/mTOR signalling pathways [107]. More recently 
in ER positive BC setting, combined inhibition of the mTOR and CDK pathways using 
vistusertib and palbociclib resulted in tumour regression in cell lines and xenografts [108]. 
Interestingly, inhibition of mTOR caused a decrease in cyclin D1 expression and consequently 
Rb phosphorylation, effects that were more profound in combination with palbociclib. 
Treatment with the mTOR inhibitor in CDK4/6 inhibitor-resistant cell lines inhibited cell 
growth via the inhibition of Rb and decreased E2F-dependent genes, effects not seen with 
palbociclib treatment alone. From these studies, it is clear that the targeting of multiple 
pathways may prove to be important i  identifying new biomarkers or providing therapeutic 
strategies for BC development and progression. However many challenges must still be 
overcome, as these pathways are essential in the regulation and maintenance of normal 
functions in non-cancerous cells. Thus, clinical trials to investigate the efficacy and safety of 
multiple pathway-targeting drugs are imperative for the advancement of combination therapy.     
 
The incorporation of triple combinations has also been explored. The use of a PIK3 inhibitor 
(BYL719) in combination with CDK4/6 inhibitor synergistically reduced BC cell viability 
[109]. Thus, the combination of ribociclib, BYL719 and letrozole is currently being 
investigated in a phase 1b trial (ClinicalTrials.gov : NCT 01872260). In addition, everolimus 
(mTOR inhibitor) combined with ribociclib and exemestane (AI) have also been trialled in 
phase 1b for the treatment of ER positive BC (ClinicalTrials.gov : NCT 01857193). The 
outcomes of these trials may give an insight on the safety and efficacy of combined treatment 
strategies and could prove to be an effective approach as a combination agent.  
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Since chemotherapy require cycling cells to be effective, CDK4/6 inhibition antagonises their 
effects and they are therefore not advised to be used in conjunction [110,111]. Thus, efforts 
have been made to investigate suitable scheduling for cytotoxic administrations in between 
CDK4/6 inhibition so that cycling cells are targeted without the antagonising effects of the 
inhibitor [112]. However, translating this into the clinic may still pose a challenge as 
proliferation rates within tumours are highly variable.  
 
Conclusions 
Although the progress of CDK4/6 inhibitors from preclinical studies to clinical trials has 
proved successful, a number of concerns remain over the use of CDK4/6 inhibitors. For 
example, treatment schedules are still in need of optimisation, particularly when used in 
combination with cytotoxic chemotherapy and/or radiotherapy. It is also important to 
recognise that cancers will have the ability to acquire resistance to highly specific CDK4/6 
inhibitors, already observed in a number of solid tumours as well as BC [88,113,114]. That 
high specificity towards CDK4/6 may constitute a drawback is supported by data from 
preclinical in vitro and in vivo studies showing that using non-specific CDK inhibitors 
(dinaciclib and purvalanol) result in an elevated lethal effect in triple negative BC [115,116]. 
Resistance may be due to other CDKs are compensating in response to CDK4/6 inhibition 
(amplification of CDK6 or suppression of CDK2 inhibitors (p27kip1) for example), however 
this mechanism is poorly understood. 
 
Preclinical data has provided vital information on CDK inhibitors and has proved pivotal for 
their subsequent clinical development. Although the safety and efficacy has improved with the 
development of more specific CDK inhibitors, moderate adverse events remain an issue. 
Combination therapy with the CDK inhibitors show comparable improvements in progression 
free survival in BC patients to those obtained using endocrine monotherapy. Despite the very 
promising improvement in progression free survival in response to CDK4/6 inhibitors, most 
studies have yet to demonstrate a corresponding positive effect on overall survival (due to the 
lack of reported deaths), generating some concern that aggressive treatment-resistant tumours 
would emerge on therapy. However, many trials were not powered to assess effects on overall 
survival, and for others longer follow up is required before positive effects can be esta lished. 
In support of this, a recent pre-planned interim analysis of the MONALEESA-7 trial reported 
significantly longer overall survival when the CDK4/6 inhibitor ribociclib was added to 
endocrine therapy in patients with advanced, hormone-receptor–positive, HER2-negative 
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breast cancer [97]). It is highly promising that the improved overall survival in patients 
receiving ribociclib compared to placebo was consistent with the improved progression free 
survival previously reported in this trial [96]. As further trials mature, it will become clear 
whether prolonged progression free survival translates into improved overall survival in 
different patient populations and with different combinations of agents.  
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Table 1. Summary of the development of CDK inhibitors  
Table 2. Clinical development of third generation CDK4/6 inhibitors 
 
Figure1. The role of estrogen in endocrine-mediated cell proliferation and survival 
Upon estrogen (E) binding, the estrogen receptor (ER) recruits co-activator complexes (CoA) 
and localises on specific DNA sites to initiate the transcription of growth factor genes as w ll
as receptor tyrosine kinases that go on to mediate proliferation, survival and growth. 
Cytoplasmic ER can also bind to receptor tyrosine kinases in response to estrogen stimulation 
resulting in activation of downstream kinase pathways. Aromatase inhibitors act by inhibiting 
the aromatase enzyme. This enzyme is responsible for the conversion of androgens into 
estrogens. This results in the decreased levels of estrogen. Selective estrogen receptor 
modulators/ degraders (SERM and SERD respectively) target the ER. SERMs bind and 
antagonise the ER thereby preventing estrogen-mediated signalling. SERDs also bind to ERs 
and inhibits dimerization, thus it is unable to form complexes or function correctly and 
consequently degraded. 
 
Figure 2. Cell cycle phases  
The cell cycle progresses through a number of phases in order to commence with a successful 
division process. Cells prepare for cell division by using the gap phases to duplicate proteins, 
organelles and DNA. During the first gap phase, G1, the cell assesses the internal a d external 
environments to determine its ability to progress through to the next phase. If conditions are 
unfavourable, the cell will leave the cell cycle and remain in a resting phase, G0, where it will 
remain dormant until stimulation from external factors. If, however, the conditions are 
favourable, the cell will progress into the S phase where DNA synthesis occurs. The second 
gap phase, G2, commences to allow for DNA replication. Provided that there have been no 
delays, damage or inhibition at previous stages, the cell will continue into the final stage of 
division, the mitotic (M) phase, where mitosis and cytokinesis are initiated. Passage from one 
phase to another is tightly regulated by checkpoints. These ensure that essential checks have 
been undertaken in order for the cell to correctly reproduce its genetic material with no errors 
that may result in the death of the cell, or in the case of cancer, aberrant cell prolif ration. 
Under normal, resting, conditions, Rb exists in an inhibitory complex with E2F and other 
corepressors. If cell division is initiated, cyclin/CDK complexes are activated to phosphorylate 
RB, lifting its inhibitory function and allowing transcription of cell cycle genes. CDK 
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inhibitors target CDKs and inhibit their function, this results in Rb remaining in an 
unphosphorylated state and the cell remains in the resting phase. 
 
Figure 3. Schematic overview of the PI3K/AKT/mTOR pathway.  
Upon ligand binding, the receptor tyrosine kinase (RTK) activates PI3K which in turn 
phosphorylates PI(4,5)P2 and converts it to PI(3,4,5)P3. PI(3,4,5)P3 activates AKT by 
phosphorylating its serine-308 and threonine-473 residues. Once activated, AKT stimulates a 
cascade of downstream signals, including the nuclear accumulation of cyclin D, that promote 
cellular growth, survival and proliferation. Phosphorylated AKT also activates mTOR which 
forms the TORC1 complex. mTOR then targets downstream signalling molecules that result in 
the synthesis of proteins that play a role in maintaining survival and promoting proliferation. 
Genetic mutations lead to constitutive activation of the PI3K/AKT/mTOR pathway and are 
common in BC. Thus, the development of inhibitors (yellow and red hexagons) have allowed 
for the disruption of these pathways in an attempt to impede aberrant cell behaviour as shown 
by the dashed lines.           
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